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Abstract 
 
Abnormal Ca
2+
 homeostasis is often associated with chronic cardiovascular diseases, such as 
hypertension, heart failure or cardiac arrhythmias, and typically contributes to the basic ethiology 
of the disease. Pharmacological targeting of cardiac Ca
2+
 handling has great therapeutic potential 
offering invaluable options for the prevention, slowing down the progression or suppression of 
the harmful outcomes like life threatening cardiac arrhythmias. In this review we outline the 
existing knowledge on the involvement of malfunction of the ryanodine receptor and the Na
+
-
Ca
2+
 exchanger in disturbances of Ca
2+
 homeostasis and discuss important proof of concept 
pharmacological studies targeting these mechanisms in context of hypertension, heart failure, 
atrial fibrillation and ventricular arrhythmias. We emphasize the promising results of preclinical 
studies underpinning the potential benefits of the therapeutic strategies based on ryanodine 
receptor or Na
+
-Ca
2+
 exchanger inhibition. 
 
Keywords: Ca
2+
 homeostasis, intracellular Ca
2+
 concentration, Na
+
-Ca
2+
 exchanger, ryanodine 
receptor, heart failure, cardiac arrhythmia. 
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Abbreviations 
RyR2: ryanodine receptor Ca
2+
-release channel type 2 
NCX1: Na
+
-Ca
2+
-exchanger type 1 
SR: sarco(endo)plasmic reticulum 
TRPC6: Transient receptor potential-like channel 6 
NKA: Na
+
-K
+
-ATP-ase 
ATP: adenosine-triphosphate 
CamKII: Ca
2+
/calmodulin-dependent protein kinase II 
ICa : L-type Ca
2+
-current 
EAD: Early afterdepolarization 
DAD: Delayed afterdepolarization 
TdP: torsades de pointes tachycardia 
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1. Introduction 
 
Ca
2+
 as a universal messenger is involved in the regulation of many physiological 
processes. In the heart Ca
2+
 plays a central role in the excitation-contraction coupling and also in 
the diastolic and systolic function of cardiomyocytes. In addition, Ca
2+
 signals are important in 
orchestrating the development, growth and differentiation of cardiac cells. Proper Ca
2+
 handling, 
therefore, is critically important in the maintenance of normal physiological function. Gene 
expression levels and activity of kinases and phosphatases, ion channels, exchangers and 
transporters are typically modulated by Ca
2+
 signals. High dynamic gain, the ability of rapid 
propagation and the precise spatial and temporal regulation are unique features of these Ca
2+
 
signals, but at the same time, they also represent important requirements for Ca
2+
 homeostasis to 
be meet in order to maintain normal function. Disturbance to any aspect of Ca
2+
 handling, on the 
other hand, leads to suboptimal function and is often associated with chronic diseases, such as 
hypertension, vascular and cardiac hypertophy, or heart failure. While the mechanistic details of 
Ca
2+
 homeostasis are being unraveled, pharmacological targeting of malfunctional Ca
2+
 handling 
has been considered to be a very attractive and promising therapeutic strategy for a long time. 
In this review, we focus on two key components of the Ca
2+
 handling: the cardiac-specific 
isoform of the ryanodine-receptor-Ca
2+
 release complex (RyR2), an important source of Ca
2+
 
from the sarco-endoplasmic reticulum (SR) and the Na
+
-Ca
2+
 exchanger type 1 (NCX1), which is 
abundantly expressed in the cardiovascular system. NCX1 is the major Ca
2+
 removal mechanism 
when operating in forward mode, while it is also involved in regulatory Ca
2+
 influx through its 
reverse mode activity. We will show that dysregulation of the RyR-NCX axis plays a central role 
in cardiovascular pathology, leading to Ca
2+
 mishandling and generation of pathological Ca
2+
 
signals, which may further worsen the diseased state. Although the experimental pharmacology 
is quite promising in this field, the question whether pharmacological targeting of RyR or NCX 
function might be beneficial in the human therapy remains to be clarified. By discussing 
important proof of concept studies, we aim to evaluate the therapeutic potential of NCX and RyR 
inhibition in cardiovascular diseases. 
 
2. Role of NCX in the development of hypertension 
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Hypertension is one of the most prevalent cardiovascular diseases. Its most dangerous 
features are that its damaging effect on various organs often remains hidden for a long period of 
time and it represents an important risk factor for the development of many cardiovascular 
diseases, including atherosclerosis, ischemic heart disease, atrial fibrillation, heart failure and 
renal diseases. In spite of the multitude of anti-hypertension drugs, many hypertensive patients 
are left uncontrolled. Therefore, the identification of novel compounds and novel therapeutic 
targets is still a priority.  
Involvement of the reverse NCX1 activity as a Ca
2+
entry mechanism in maintaining the 
vascular tone has long been recognized (Slodzinski and Blaustein, 1998). Indeed, through co-
localization and/or functional coupling with membrane receptors, ion channels and intracellular 
messengers, NCX appears to play a role in integrating the different vasoactive neurohormonal 
signals (Syyong et al., 2007). Co-localization of different transporters in functional micro- or 
nanodomains allows the Ca
2+
 influx or efflux via NCX to respond to the local changes in 
submembrane Ca
2+
 and Na
+
 concentration (Lynch et al., 2008; Poburko et al., 2008). For 
example, NCX is co-localized with the transient receptor potential-like channel 6 (TRPC6), a 
non-specific cation channel, through which the Na
+
 influx and the elevated local Na
+
 
concentration can increase the reverse mode NCX activity, resulting in net Ca
2+
 influx (Pulina et 
al., 2013). A further peculiarity of this pathway is the proximity of NCX and the 
sarco(endo)plasmic reticulum Ca
2+
-ATP-ase, that finally allows the Na
+
 influx to regulate the SR 
Ca
2+
 content (Kuszczak et al., 2010). Similar coupling has been described between NCX and the 
alpha2 isoform of the Na
+
-K
+
-ATP-ase (NKA) (Zhang et al., 2005) (Hauck and Frishman, 2012), 
which has been shown to participate in the regulation of vascular tone and development of 
hypertension induced by endogenous ouabain (Blaustein et al., 2012).  
The role of the subcellular anatomical and functional coupling between the Na
+
 and Ca
2+
 
handling transporters appears to be augmented during the development of hypertension. Hamlyn 
et al. showed that the increased ouabain level may contribute to the chronic hypertensive effect 
of angiotensin-II, by increasing NCX and TRPC6 expression, which in turn shifts vascular ionic 
homeostasis towards a higher vascular tone and responsiveness (Hamlyn et al., 2014). In line 
with this, elevated expression of NCX and other ion channels involved in Ca
2+ 
homeostasis, such 
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as TRPC6, and the concomitant augmentation of Ca
2+ 
signaling has been documented in animal 
models of hypertension (Taniguchi et al., 2004; Zulian et al., 2010). 
Thus, based on the central role of NCX, decoupling of the pathological neurohormonal 
activation and the intracellular Ca
2+ 
signaling by inhibition of the Ca
2+ 
influx via reverse NCX 
seems to be a logical way to prevent or treat hypertension. 
 
3. Pharmacological evidence for the antihypertensive effect of NCX inhibition  
 
As we have seen above, increased NCX activity is an inevitable factor in hypertension, 
which makes evaluation of pharmacological NCX inhibition in antihypertensive therapy logical. 
Because of the multiple roles of NCX in the vascular system, possible antihypertensive effect of 
pharmacological NCX inhibition can only be evaluated by in vivo trials. However, the number of 
studies addressing this issue are surprisingly sparse, although even studies with negative results 
would be equally important for the antihypertensive research.  
The first study showing pharmacological evidence for the involvement of reverse NCX in 
hypertension has been done using a rodent model of Cushing’s syndrome. In this work the 
adrenocorticotropic hormone-induced hypertension has been effectively prevented by chronic 
administration of KB-R7943, a reverse NCX inhibitor (Dostanic-Larson et al., 2005). 
Excessive dietary salt intake is known to be an important factor in the development of 
hypertension (Blaustein et al., 2012). In this case the increased Ca
2+ 
influx to the smooth muscle 
cell results from the increased Na
+
 load-induced shift of NCX function towards its reverse-mode 
activity. Thus, its pharmacological inhibition should be logically antihypertensive. Indeed, 
selective knock-out of NCX in smooth muscle has been shown to prevent the development of 
angiotensin-II-dependent salt-induced hypertension (Wang et al., 2015). In spite of the clear-cut 
pathology in this case, only a few pharmacological studies attempted to explore this therapeutic 
possibility. Chronic administration of SEA0400 exerted a significant antihypertensive effect in 
different models of salt-dependent hypertensive rats, including deoxycorticosterone acetate-salt 
hypertensive, salt-loaded Dahl salt-sensitive, and salt-loaded spontaneously hypertensive rats 
(Iwamoto et al., 2004). Furthermore SEA0400 was able to reduce vascular hypertrophy and renal 
dysfunction, factors that exacerbate the progression of hypertension. In acute experiments 
SEA0400 also displayed a marked vasodilatation when infused into the systemic circulation 
 7 
suggesting again the crucial role of NCX in maintenance of the abnormal vascular tone. 
However, SEA0400 was not able to modulate the blood pressure in normotensive rats or salt-
independent hypertensive animals. 
The different response to SEA0400, which depends on blood pressure and its salt-
dependency, may be related to the fact that the effect SEA400 apparently depends on [Na
+
]i, 
since it facilitates the Na
+
-dependent inactivation of NCX, which is sufficiently augmented by 
the higher Na
+
 influx in the case of salt-dependent hypertension (Iwamoto and Kita, 2006). It 
appears, therefore, that SEA400 can be therapeutically effective in salt-dependent hypertension 
only. Thus, novel NCX inhibitors with different mechanism of action are required to study the 
potential antihypertensive effect of NCX inhibition in other types of hypertension. 
 
4. Altered NCX function and RyR dysfunction in heart failure 
 
Incidence of heart failure is continuously increasing in the developed world. There are a 
number of predisposing conditions promoting heart failure, such as hypertension and ischemic 
heart disease. Heart failure may have multiple origin and divers manifestations with distinct 
ethiologies (e.g. familiar, diastolic or systolic heart failure, etc.), but it can be considered as a 
common outcome of various cardiovascular diseases. Modern pharmacological therapies can 
significantly slow the progression of heart failure by suppressing the sympathetic tone with beta 
blockers or by inhibiting the pathologically activated renin-angiotensine-system with and ACE-
inhibitors. Still, heart failure mortality is high, with cardiac arrhythmias being many times the 
direct cause of death. It would therefore be highly beneficial to focus on prevention and further 
slowing of disease progression, potentially by using novel pharmacological targets. 
Heart failure is characterized by insufficient pump function and electrical remodeling with 
cellular basis involving altered regulation of Ca
2+ 
handling (Ottolia et al., 2013). One of the most 
important functional changes is the increased [Na
+
]i, with a consequently increased reverse mode 
NCX activity (Despa and Bers, 2013). On the other hand, elevated expression level of NCX has 
also been observed in many models in the state of established heart failure (Lugenbiel et al., 
2015; Mishra et al., 2005), and increased NCX expression appears to be a key alteration during 
the transition to heart failure, foregoing the changes in the expression of other Ca
2+ 
handling 
proteins like SERCA (Rodriguez et al., 2014). Increased reverse mode NCX activity may 
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contribute to the maintenance of contractility by two distinct mechanisms. First, the elevated Ca 
influx supports Ca
2+ 
filling of the SR. Second, upregulated reverse mode NCX may also increase 
the Ca
2+
 cycling by directly facilitating the Ca
2+
-induced Ca
2+
 release from the SR (Hobai and 
O'Rourke, 2000). However, increased Ca
2+ 
efflux via forward mode NCX favors Ca
2+ 
loss 
resulting in a reduced net SR Ca
2+ 
content. 
Another critical alteration in heart failure is the Ca
2+ 
leak from the SR, due to increased 
phosphorylation of RyR by the calcium/calmodulin-dependent protein kinase II (CaMKII). 
CaMKII phosphorylation destabilizes RyR, which results in spontaneous Ca
2+ 
release 
independent of the Ca
2+
 stimulus (Marx and Marks, 2013). On one hand, SR Ca
2+ 
leak tends to 
lower the SR Ca
2+ 
content with a consequent reduction of systolic Ca
2+ 
transient and contractile 
force. Furthermore, the uncontrolled Ca
2+
 release is an important arrhythmogenic factor in heart 
failure (see below). It must be noted that development of heart failure always results from 
complex structural and electrophysiological changes, associated with altered gene expression 
pattern (Zarain-Herzberg et al., 2011). However, recent studies suggest that pharmacological 
modulation of the function of NCX and RyR, the two key players in Ca
2+ 
handling, can 
potentially be beneficial in the treatment of heart failure. 
 
5. Possible improvement by pharmacological NCX inhibition of the defective Ca
2+ 
cycling in heart failure  
 
Upon the recognition of the role of NCX in heart failure pathophysiology, the potential 
beneficial effect of NCX inhibition in correcting the low SR Ca
2+ 
load has been emphasized by 
several review papers. The available pharmacological evidence, however, is still sparse. 
Regarding the malfunctional Ca
2+ 
cycling, NCX inhibition (based on the suppressed forward 
mode activity) could theoretically cause a positive inotropic response, since the weaker Ca
2+ 
extrusion favors the Ca
2+ 
uptake into SR by SERCA, resulting in an increased SR Ca
2+ 
load. 
However, as long as selective inhibition of forward mode NCX activity is not achieved, NCX 
inhibition will decrease reverse mode NCX activity as well, neutralizing the stimulating effect of 
reverse mode NCX. 
In addition, some studies suggest that the first candidate of selective NCX inhibitors, 
SEA0400 has been shown to be more effective on the reverse than on the forward mode activity 
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of NCX (Lee et al., 2004). It is not surprising, therefore, that the putative positive inotropic effect 
was detected neither in heart failure animal models, nor in normal control animals. Under 
physiological conditions SEA0400 was not able to increase contractions either in myocytes 
isolated from canine hearts, or in hearts isolated from rabbits and guinea pigs (Birinyi et al., 
2008; Farkas et al., 2008; Szentandrassy et al., 2008). In addition, SEA0400 appeared to block L-
type Ca
2+
 current (ICa) too, which may also limit the putative positive inotropic action (Birinyi et 
al., 2005). These results were further supported by the finding that SEA0400 was able to prevent 
the reverse NCX-mediated positive inotropy when [Na
+
]i was elevated, but it failed to affect cell 
shortening under normal conditions in canine myocytes (Nagy et al., 2014). 
However, positive inotropic effect of NCX inhibition by SEA0400 can also be seen under 
experimental conditions where reverse NCX does not play a substantial role in ECC. Application 
of KB-R7943, a relatively selective reverse mode NCX inhibitor, did not result in negative 
inotropic effect in rat myocytes, in line with the fact that Ca
2+ 
influx via reverse mode NCX does 
not contribute to the Ca
2+
-induced Ca
2+ 
release in this species (Satoh et al., 2000). In accordance 
with this, inhibition of the Ca
2+ 
efflux mode of NCX by SEA0400 was able to cause a significant 
positive inotropy in rat ventricular myocytes (Acsai et al., 2007). 
In some animal models of heart failure, NCX inhibition by SEA0400 has been reported to 
have different outcomes regarding the inotropic effect, depending on the experimental model 
used. SEA0400 increased contractility in myocytes isolated from mice with transverse aortic 
constriction, but not in myocytes from MLP -/- mice (Ozdemir et al., 2008). This apparent 
controversy suggests that the outcome of NCX inhibition is essentially dependent on the various 
concomitant Ca
2+ 
handling alterations. Another NCX inhibitor, SN-6 has been found to evoke 
negative inotropic action in normal and also in failing cardiomyocytes, supposedly because of 
the substantial inhibitory effect on ICa (Gandhi et al., 2013). 
Generally, the lack of positive inotropic effect has been explained on the basis of 
simultaneous inhibition of Ca
2+ 
influx via the reverse mode NCX and ICa (Bourgonje et al., 
2013). Thus, the putative improvement of systolic Ca
2+
 in heart failure requires further studies, 
ideally with application of new, more selective forward mode NCX blockers (i.e. with less effect 
on ICa and more pronounced inhibition on forward mode NCX). 
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6. Pharmacological stabilization of RyR improves defective Ca
2+ 
cycling in heart 
failure 
 
Recent studies show that cessation of the abnormal Ca
2+ 
signaling by inhibiting CamKII 
activity may ameliorate RyR hyperphosphorylation and the consequent abnormal RyR activity, 
resulting in normalized Ca
2+ 
handling (Tzimas et al., 2015; Westenbrink et al., 2013), but the 
pharmacology of this strategy is still in its infancy. However, cessation of the abnormal signaling 
can also be achieved by application of dantrolene, an old drug used as a skeletal muscle relaxant 
agent against spastic diseases and malignant hyperthermia in human clinical practice. Dantrolene 
appears to act specifically on dysfunctional RyR, and although it inhibits other ion channels, like 
some K
+
 and Ca
2+ 
channels (Acsai et al., 2015), its stabilizing effect on dysfunctional RyR 
surpasses these non-specific side effects. Therefore, dantrolene can be considered to be disease-
specific (Maxwell et al., 2012).  
Application of dantrolene has been proved to alleviate the abnormal RyR activity and 
restore normal Ca
2+ 
cycling. It suppressed the aftercontractions caused by Ca
2+ 
overload, 
increased SR Ca
2+
 load, exerted positive inotropy and improved diastolic relaxation in isolated 
hamster heart (Satoh et al., 1997). Similar effects of dantrolene have been found in isolated rat 
papillary muscles (Meissner et al., 1996). More importantly, dantrolene displayed similar 
beneficial effects in cardiac preparations from patients with end-stage heart failure (Meissner et 
al., 1999). It also improved cardiac function in vivo in rats with ischemic heart failure (Min et al., 
2003), increased SR Ca
2+ 
content and exerted positive inotropic effect in chronic heart failure 
models of dogs (Kobayashi et al., 2009) and rabbits (Maxwell et al., 2012). All these beneficial 
effects on Ca
2+ 
handling may be based on the inhibition of SR Ca
2+ 
leak by stabilizing the RyR 
suggesting that multiple aspects of the cardiac dysfunction can be improved by restoration of 
normal RyR function. Thus, it can be concluded that dantrolene, although characterized as a RyR 
inhibitor, displays specificity for dysfunctional RyR, inhibiting the aberrant RyR opening but 
leaving its normal function relatively unchanged. This unique feature of dantrolene makes it 
potentially useful in the case of the destabilized RyR in heart failure, where suppression of 
abnormal function is as important as maintenance of normal activity. 
 
7. Myocardial remodeling is closely associated with abnormal Ca
2+ 
handling 
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Another important aspect of heart failure is the development of structural remodeling in 
chronic cases. This involves hypertrophy of cardiomyocytes and increased tissue fibrosis. At 
early stages, myocardial remodeling can be a helpful compensatory response to the increased 
load, which helps to maintain the compensated stage of the disease. However, it is associated 
with increased risk of arrhythmias by presenting the structural substrate for arrhythmogenesis. 
Recent studies indicate that abnormal Ca
2+ 
signaling and Ca
2+ 
handling play a crucial role in 
the induction and progression of adverse remodeling in myocardial cells as well as in cardiac 
fibroblasts (Chen et al., 2010). Again, CamKII-dependent signaling is implicated in connecting 
the increased neurohormonal activation to the abnormal Ca
2+
-dependent regulation of cell 
function (Mollova et al., 2015). Accordingly, involvement of NCX upregulation and altered 
phosphorylation status play a key function in remodeling (Gupta et al., 2009; Katanosaka et al., 
2007; Valdivia et al., 2015). Similar role of NCX in pathogenesis of atrial remodeling associated 
with atrial fibrillation has also been reported (see below). It is worth to note that the well known 
anti-remodeling effect of the angiotensin-II type 1 receptor blocker drugs in heart failure appears 
to be associated with the restoration of the physiological status of Ca
2+ 
signaling and Ca
2+ 
handling proteins, including the lowering of the increased NCX expression (Ferreira et al., 
2011). On the other hand, abnormal NCX function can also be activated directly by the abnormal 
neurohormonal regulation. Endogenous ouabain is increased in many patients, which is known to 
contribute to the development of fibrosis by induction of collagen production in fibroblasts 
(Fedorova et al., 2010). Since the primary action of digitalis-like factors is the inhibition of NKA 
with the consequent increase of [Na
+
]i and activation of the reverse mode NCX (resulting in Ca
2+
 
influx), it seems logical to speculate that the increased Ca
2+ 
signaling due to reverse mode NCX 
activity may contribute to induction of remodeling. 
This latter hypothesis has been addressed by Kamimura et al.using SEA0400 as a 
pharmacological tool. They found that chronic administration of SEA0400 at doses not affecting 
hypertension was able to reduce the myocardial remodeling in Dahl salt-sensitive hypertensive 
rats, and consequently improved the survival of the animals (Kamimura et al., 2012). This 
beneficial effect was attributed to the inhibition of fibrosis development by blocking the reverse 
mode NCX, since SEA0400 also suppressed the increased activity of cardiac fibroblasts.  
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Another study used KB-R7943 to provide evidence for the role of reverse mode NCX in 
mediating Ca
2+ 
signals associated with induction of human cardiac fibroblast proliferation 
through different pathways (Ikeda et al., 2013), but to our best knowledge the study of 
Kamimura et al. is the only one demonstrating that NCX inhibition may be promising to delay 
the adverse remodeling associated with heart failure in a chronic pharmacological experiment.  
It is also worth to mention that the Ca
2+ 
sensitizer levosimendan, used in the human 
therapy, has been reported to decrease the hypertension-induced cardiac remodeling in 
hypertensive Dahl/Rapp rats, resulting improved survival of the animals (Louhelainen et al., 
2007). This seems to be particularly interesting in the light of the newly discovered NCX 
inhibitory effect of levosimendan (Li et al., 2014). Li et al. have shown that levosimendan 
inhibits the membrane trafficking of NCX, and consequently its activity in cardiomyocytes 
derived from human cardiomyocyte progenitor cells. Although these observations need to be 
confirmed in more complex experimental systems, they strongly suggest that the NCX inhibitory 
effect may contribute to the anti-remodeling activity of levosimendan. 
SR Ca
2+ 
signaling through RyR also appears to play a central role in remodeling. On the 
one hand, regulation of RyR by CamKII has been implicated in cardiac remodeling and heart 
failure (Chakraborty et al., 2014). On the other hand, RyR activity itself seems to affect other 
pathways and gene expressions involved in hypertrophy (Zou et al., 2011). Pharmacological 
studies support this central role, since inhibition of aberrant RyR activity has been shown to 
ameliorate remodeling in different models. Chronic treatment of dogs with JTV519 (K201), a 
nonspecific RyR stabilizer, was able to prevent left ventricular remodeling in a pacing-induced 
canine heart failure model and ameliorated the severity of heart failure (Yano et al., 2003). The 
authors also provided molecular evidence for the protection against RyR hyperphosphorylation 
and they have shown in acute experiments that JTV519 suppressed the SR Ca
2+ 
leak.  
Another drug which is useful to study the anti-remodeling consequences of RyR inhibition 
is dantrolene. The RyR stabilizer effect of this agent has been demonstrated in several in vitro 
studies that simulated the abnormal inter-domain interaction within the RyR complex 
(Gangopadhyay and Ikemoto, 2010; Hamada et al., 2009). These studies have shown that 
application of dantrolene effectively inhibited the hypertrophic alterations induced by 
endothelin-1 or DPc10 (a destabilizer of the RyR) in neonatal rat cardiac myocytes. Furthermore, 
protective action of dantrolene has also been demonstrated under in vivo conditions. Chronic 
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dantrolene treatment of hypertensive rats with aortic constriction effectively inhibited the 
development of myocardial hypertrophy (Ohkusa et al., 1998), increased survial, prevented the 
structural and molecular remodeling and also the functional deterioration of the hearts in rats 
with doxorubicin-induced cardiomyopathy (Campos et al., 2011). 
We can conclude therefore that according to the available pharmacological evidence, 
inhibition of both NCX and RyR may display beneficial effects being promising in heart failure 
to improve contractile dysfunction and to prevent myocardial remodeling. 
 
8. Abnormal Ca
2+ 
handling as a possible antiarrhythmic target 
 
Onset of cardiac arrhythmias belongs to the most common complications and causes of 
death during the time course of the cardiovascular diseases. Several recent review papers discuss 
the arrhythmogenic mechanisms associated with Ca
2+ 
handling abnormalities occurring in 
various cardiac diseases (Driessen et al., 2014; Wagner et al., 2015). RyR and NCX play a 
crucial role in the disease-related Ca
2+
 signaling defect, and their involvement in the 
arrhythmogenesis is based on the functional coupling between the submembrane Ca
2+
 level and 
the transmembrane potential. NCX activity is highly dependent on both [Na
+
]i and [Ca
2+
]i, and 
because of the 1:3 stoichiometry of the Ca
2+
-Na
+
 antiport, it generates inward current upon 
removing Ca
2+ 
from the cytosol. In addition, along the T-tubule membrane of the ventricular 
myocytes, NCX molecules are expressed in close proximity with junctional SR, from which Ca
2+ 
is released through RyR. Thus, Ca
2+ 
release from SR and part of Ca
2+
 removal through the NCX 
occur in the same functional space called local Ca
2+
 microdomain, in which Ca
2+
 level is at least 
ten times higher than in the bulk phase of cytoplasm (Acsai et al., 2011). Once activated by 
increased local [Ca
2+
]i, NCX generates an inward current contributing to the generation of early 
(EAD) and delayed (DAD) afterdepolarizations. These elementary electrical events can promote 
ectopic beats and triggered activity, potentially leading to life threatening arrhythmias. Since the 
introduction of this concept (January and Fozzard, 1988) several studies demonstrated the 
arrhythmogenic consequences of the increased NCX activity associated with heart failure and 
atrial fibrillation, and pharmacological modulation of NCX became generally accepted as a 
possible new antiarrhythmic intervention (Antoons et al., 2012). However, the lack of potent and 
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selective NCX blockers obviously hampered the pharmacological verification of this concept, 
especially in in vivo animal models.  
On the other hand, there are some antiarrhythmic drugs in the current clinical practice, 
including bepridil, aprindine, amiodarone, dronedarone and cibenzoline that are known to inhibit 
NCX to a certain degree (Watanabe et al., 2004; Watanabe et al., 2002; Watanabe and Kimura, 
2000, 2001, 2010). Since their primary electrophysiological actions are more pronounced, these 
drugs are not suitable to study the potential protective effects of NCX inhibition per se. 
However, the concomitant NCX inhibition is likely to contribute to the beneficial effects of these 
compounds observed e.g. in atrial fibrillation (Nakatani et al., 2015).  
Investigation of the putative antiarrhythmic effects of NCX inhibition became possible with 
the development of relatively specific and selective NCX blockers. Based on the available 
evidence, NCX inhibition seems to affect arrhythmia generation differentially depending on the 
experimental conditions and the actual mechanism of arrhythmias. 
 
9. Efficacy of NCX inhibition against DAD and triggered arrhythmias induced by 
Ca
2+
-leak 
 
The first experiments showing the efficacy of NCX inhibition by SEA0400 against Ca
2+
-
overload related arrhythmia generation was carried out in canine cardiac preparations (Nagy et 
al., 2004). In this study SEA0400 effectively suppressed DAD generation and triggered 
arrhythmias induced by strophantidine and fast pacing in canine Purkinje fibers. Similar results 
have been obtained in guinea pig papillary muscles showing that SEA0400 decreased the 
ouabain-mediated positive inotropy and arrhythmias (Tanaka et al., 2007). This was further 
supported in a study using in vivo canine model where the antiarrhythmic effect of SEA0400 was 
convincing against digitalis-induced tachyarrhythmias (Nagasawa et al., 2005).  
Since digitalis induced positive inotropy is known to be mediated by increased Ca
2+ 
influx 
via reverse mode NCX, the above finding raises the possibility that the inhibition of NCX may 
reduce the incidence of Ca
2+
-dependent arrhythmias not only by reducing the [Ca
2+
]i-voltage 
gain, but also by ameliorating the Ca
2+ 
load of the cell. This is in line with the results obtained in 
single canine myocytes, where NCX inhibition completely prevented and reversed the elevated 
[Na
+
]i-induced positive inotropic effect (Nagy et al., 2014).  
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These basic studies have been followed by experiments using more sophisticated 
techniques in isolated heart. Fujiwara et al. have studied the link between proarrhythmic Ca
2+ 
waves and membrane potential oscillations using confocal imaging in isolated rat hearts 
(Fujiwara et al., 2008). Again, SEA0400 effectively decreased the arrhythmogenic membrane 
depolarizations. Furthermore, it is important to note that these authors also applied ryanodine to 
inhibit RyR, an intervention that was also able to suppress arrhythmogenesis. Thus, this study 
may underline the perspective of the potential synergistic effect between the suppression of both 
RyR and NCX. 
Involvement of the elementary electrical events in generation of disease-associated 
arrhythmias has also been demonstrated in a model of Andersen-Tawil syndrome (Radwanski 
and Poelzing, 2011). In this study KB-R7943 has been successfully applied to lower the 
incidence of tachycardia, while the enhancement of NCX activity in Ca
2+ 
removal increased the 
arrhythmia occurrence, further demonstrating the pathogenic role of NCX in arrhythmias.  
However, there are some conflicting results in the literature. It has been shown for instance 
that aconitine-induced arrhythmias are also based on Ca
2+ 
overload, DAD and triggered activity 
(Sun et al., 2014; Zhou et al., 2013), but interestingly, SEA0400 was not effective in those 
experiments where arrhythmias were evoked by aconitine (Amran et al., 2004). This may suggest 
that in more complex situations other factors than NCX (e.g. EAD generation) may contribute to 
development of arrhythmias, thus the antiarrhythmic action of NCX inhibition may not always 
be manifested.  
It must be noted regarding the above experiments that both KB-R7943 and SEA0400 can 
inhibit ICa in the cardiac cells, which raises the possibility tha the antiarrhythmic activity can also 
be attributed to the reduced Ca
2+ 
load of the myocytes. However, ORM-10103, a novel and 
selective NCX inhibitor with no direct effect on ICa, also effectively reduced the incidence of 
DADs and aftercontractions under conditions of intracellular Ca
2+ 
overload both in multicellular 
cardiac preparations and single cells (Jost et al., 2013; Nagy et al., 2014). These results strongly 
suggest that inhibition of NCX alone is able to reduce the Ca
2+
-dependent arrhythmia propensity, 
and the concomitant ICa inhibition is not necessary for the manifest antiarrhythmic effect. 
 
10. Effect of NCX inhibition on EAD related arrhythmias 
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Another potential mechanism to reduce arrhythmia propensity by NCX inhibition is 
suppression of EADs. EADs can be evoked by decreasing the repolarization power, which 
lengthens action potential duration (APD), increases beat-to-beat variability of APD and often 
leads to the development of torsades de pointes (TdP) tachycardia (Oros et al., 2010). By 
generating inward current upon Ca
2+ 
removal, NCX is thought to play an important role in 
evoking EADs either directly by depolarizing the membrane, or indirectly by allowing the 
reactivation of Ca
2+ 
and Na
+
 currents due to the slower rate of repolarization (Volders et al., 
2000). Indeed, pharmacological studies investigating the role of NCX in EAD generation have 
shown that EAD can be effectively attenuated by pharmacological NCX inhibition. In isolated 
canine ventricular preparations, both SEA0400 and ORM-10103 significantly reduced the 
incidence of EADs (Jost et al., 2013; Nagy et al., 2004), and EADs have been completely 
suppressed by SEA0400 in isolated canine myocytes (Johnson et al., 2010). These findings were 
also supported by results obtained in a more complex model of the long QT syndrome and heart 
failure in intact rabbit heart, where NCX inhibition by SEA0400 prevented EADs by reducing 
AP prolongation, dispersion of repolarization, and thereby suppressed TdP types arrhythmias 
(Milberg et al., 2008; Milberg et al., 2012). Furthermore, in a study investigating the putative 
antiarrhythmic effect of SEA0400 in dogs with chronic atrioventricular block, a model of 
compensated cardiac hypertrophy, SEA0400 was able to moderate the dofetilide-induced 
increased action potential variability and TdP, supporting the role of NCX current in the short 
term variability and EAD generation (Bourgonje et al., 2013). However, since SEA0400 was 
shown to block ICa at the concentrations used, the degree to which NCX inhibition contributes to 
the observed effects is not obvious. Nevertheless, it appears that modulation of the interaction 
between SR Ca
2+ 
release and ICa occurring in the subsarcolemmal Ca
2+ 
microdomain may be 
involved in the antiarrhythmic effect of NCX inhibition (Antoons et al., 2015).  
It must be noted however, that other study using SEA0400 in isolated rabbit hearts failed to 
find any evidence for the contribution of NCX to generation of EADs and TdP by dofetilide 
(Farkas et al., 2009). Thus, the detailed mechanism of the antiarrhythmic action of NCX 
inhibition requires further studies. 
 
11. Ischemia-reperfusion induced arrhythmias 
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As we have shown above, the pharmacological NCX inhibition may be a useful 
antiarrhythmic strategy, although the exact electrophysiological explanation for this beneficial 
effect may be difficult even in relatively simple arrhythmogenic conditions. Furthermore, the 
situation becomes more complicated when different arrhythmogenic mechanisms can exist at the 
same time. Arrhythmias generated by an ischemia-repefusion protocol are good examples for 
this complexity. Change in action potential morphology, action potential heterogeneity, 
conduction delay and its heterogeneity and Ca
2+ 
overload may exist in parallel or after each 
other, making any inferences about the putative antiarrhythmic efficacy of NCX inhibition very 
difficult in these situations. On the other hand, the pathogenetic role of NCX in mediating 
ischemia-reperfusion induced cell death and myocardial injury is well established (Baczko et al., 
2003, 2004) and indeed pharmacological NCX inhibition has been shown to be protective against 
ischemia-reperfusion injury (Namekata et al., 2005). Therefore, NCX inhibition may also 
modulate the arrhythmia outcome indirectly by ameliorating the injury of the myocardium. 
The first study reporting the antiarrhythmic potential of NCX inhibition was performed 
using an in vivo rat model (Takahashi et al., 2003). These authors applied regional ischemia 
followed by reperfusion, and found that SEA0400 decreased the incidence of ventricular 
fibrillation. However, despite of the extensively documented cardioprotective effect of NCX 
inhibition seen in ischemic-reperfused myocardium, further studies were unable to demonstrate 
the protection against ventricular arrhythmias under these conditions. In Langendorff-perfused 
rat hearts SEA0400 even increased the incidence and duration of ventricular arrhythmias induced 
by reperfusion, in spite of the observed protection of myocardium (Feng et al., 2006), while 
others failed to demonstrate any significant protection against cardiac arrhythmias associated 
with regional ischemia-reperfusion injuries in dogs in vivo (Nagasawa et al., 2005). Interestingly, 
the antiarrhythmic effect of SEA0400 was convincing against digitalis-induced tachyarrhythmias 
in the same study, thus the authors concluded that NCX inhibition can be effective only in Ca
2+
-
dependent arrhythmias by reducing the depolarizing NCX current. Similar conclusion has been 
made in a recent study, which compared the antiarrhythmic effect of SEA0400 and ORM10103 
in isolated Langendorff-perfused rat hearts (Szepesi et al., 2015). Both compounds appeared to 
reduce the incidences of extra beats, but not the duration and incidences of ventricular 
tachyarrhythmias, suggesting again that NCX inhibition may be effective against EAD and DAD 
generation, but not in reducing reentry-based sustained arrhythmias. Similarly, in a chronic 
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model of myocardial infarction in rabbit, KB-R7943 suppressed afterdepolarizations and the 
concomitant spontaneous tachyarrhythmias, but the inducibility of tachyarrhythmias was 
increased at the same time (Chang et al., 2015b), presenting again an example for the difficulties 
arising from the coexistence of various arrhythmogenic conditions. 
 
12. Antiarrhythmic effect of RyR inhibition 
 
Inhibition of pathological RyR activity is an emerging antiarrhythmic mechanism. The 
protective effect of dantrolene against dysrhythmias associated with serious conditions like 
malignant hyperthermia has been attributed historically to its inhibitory effect on the Ca
2+ 
and K
+
 
currents (Acsai et al., 2015). However, recent studies have shown that the underlying mechanism 
is more specific and is related to inhibition of the uncontrolled Ca
2+ 
release by stabilization of the 
RyR complex. Based on this effect, dantrolene was shown to effectively reduce the arrhythmia 
incidence in various cardiac situations like ischemia-reperfusion, heart failure or 
catecholaminergic polymorphic ventricular tachycardia (CPVT). The antiarrhythmic effect of 
dantrolene observed in experimental models of heart failure has been attributed to the normalized 
Ca
2+ 
handling (Kobayashi et al., 2009; Maxwell et al., 2012), which was reflected by the reduced 
spontaneous Ca
2+
 spark frequency and consequently the arrhythmogenic membrane potential 
oscillations. Furthermore, in the whole heart level the inhibition of the cellular arrhythmogenic 
events has been manifested as an effective protection against ventricular ectopic activity in 
isolated failing rabbit hearts , (Chou et al., 2013). 
CPVT is an inherited genetic disorder with potentially lethal outcome. It is caused by 
different mutations in the RyR gene, which results in uncontrolled Ca
2+ 
release upon adrenergic 
stimulation leading to afterdepolarizations and VT. Application of dantrolene or other drugs with 
RyR inhibitory effect may be therefore a logical choice against CPVT. Indeed, when patients 
responded surprisingly well to Na
+
 channel inhibitors like flecainide, it turned out that this drug 
has an inhibitory effect on RyR (Hilliard et al., 2010). However, suppression of Ca
2+ 
release 
events can also be explained on the basis of Na
+
 channel inhibition per se (Radwanski et al., 
2015), thus the current debate regarding the contribution of Na
+
 channel blockade and RyR 
stabilization to the beneficial effect reflects the difficulties arising from the lack of selectivity. 
Nevertheless, dantrolene with its primary effect on RyR has been proved to be very efficient in 
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pharmacological studies. In an in vivo mouse model of the disease, chronic treatment with 
dantrolene effectively reduced the occurrence of VT induced by epinephrine or physical exercise 
(Kobayashi et al., 2010). Cellular studies have also supported these findings, by showing that the 
elevated Ca
2+ 
spark frequency displayed by mutant cells in response to isoproterenol could be 
corrected with acute application of dantrolene (Suetomi et al., 2011; Xu et al., 2010). 
Ventricular fibrillation (VF) is the most serious arrhythmia leading to death within minutes, 
and represents the most frequent form of the sudden cardiac death. Despite of the effective 
resuscitation techniques, the mortality rate of VF is extremely high, and this may occur at any 
stage during the time course of heart failure. VF is characterized by fast, repetitive activation of 
myocytes due to development of reentrant circuits within the electrical conduction pathway. 
Because of these fast repetitive activations, intracellular Na
+
 and Ca
2+ 
overload occurs 
contributing to Ca
2+ 
oscillations, the consequent electrical instability and myocardial dysfunction 
even after successful defibrillation (Zaugg et al., 1998). An early study showing the increased 
fibrillation threshold after dantrolene administration in rats (Brooks et al., 1989) has been 
followed by a recent study demonstrating that cessation of the abnormal Ca
2+ 
cycling by 
applying dantrolene to inhibit RyR effectively ameliorated the postfibrillatory ventricular 
dysfunction in pigs in vivo (Zamiri et al., 2014). In addition, dantrolene facilitated the success of 
defibrillation and decreased the number of refibrillation episodes. Although these observations 
may represent a promising new strategy against VF, it must be noted that the dantrolene-induced 
elongation of action potential duration might also be involved in the protective effect. Therefore 
further studies are required to confer the antifibrillatory action of RyR inhibition - ideally using a 
compound with a selective RyR stabilizer effect. S107 is a new agent with apparently more 
selective RyR inhibitory effect (Mei et al., 2013), although it is not widely used at present. It is 
also important to note that because of the well established role of NCX in electrical instability, a 
synergistic interaction between inhibition of RyR and NCX can be anticipated against VF, but 
this requires further support by detailed studies. 
Finally, it is also known that Ca
2+ 
overload of the myocyte developed during an ishemia-
reperfusion episode profoundly contributes to the cellular dysfunction and arrhythmia 
generation. However, since ischemia-reperfusion presents a complex scenario regarding the 
arrhythmogenic mechanisms, it is not surprising that there are conflicting results with use of 
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dantrolene, with some studies well demonstrating its antiarrhythmic action (Brooks et al., 1989), 
while others could not find any protection (Pelleg et al., 1985; Preckel et al., 2000).  
In conclusion, several studies demonstrated that both NCX and RyR inhibition display 
direct antiarrhythmic actions under various conditions. In addition, the antiremodeling effects of 
NCX and RyR inhibitors (see above) may also reduce the arrhythmia propensity indirectly by 
reducing cardiac fibrosis (Morita et al., 2014). 
 
13. Pathological Ca
2+ 
mishandling in atrial fibrillation 
 
Atrial fibrillation belongs to the most common cardiac arrhythmias which represents an 
increased risk for stroke. Conversion to sinus rhythm is often impossible because of the fast 
development of structural and electrical remodeling. Electrical remodeling occurring in atrial 
fibrillation involves alterations primarily in the repolarizing K
+
 currents, but abnormal changes 
in Ca
2+ 
handling transporters may also play a prominent role (Lugenbiel et al., 2015). Increased 
expression and activity of NCX appears to be a key factor also in atrial fibrillation associated 
with non-steroidal anti-inflammatory drugs (Chang et al., 2015a) and taurocholic acid (Rainer et 
al., 2013). Also, increased NCX activity has been reported to exert fibrillatory effects in atrial 
fibrillation induced by endothelin-1 and angiotensin-II in atrial myocytes (Chen et al., 2006; Li et 
al., 2005). Indeed, angiotensin-II induced EADs could be prevented by using SEA0400 to block 
NCX in cultured human atrial myocytes (Tsai et al., 2011). 
As a consequence of dysfunctional RyR activity, Ca
2+
 leak from the SR plays also a central 
role in atrial fibrillation. Abnormal RyR activity can be caused by several factors. For example, 
reduced atrial junctiophilin-2 level or loss of function mutation may lead to SR Ca
2+
 leak due to 
the hampered junctiophilin-2 mediated RyR stabilization (Beavers et al., 2013). 
Hyperphosphorylation of RyR by activated CaMKII also may promote SR Ca
2+
 leak (Voigt et 
al., 2012). Whatever the cause should be, the abnormal Ca
2+ 
release is immediately coupled to 
the development of DADs through forward mode NCX activity (see above), which may evoke 
triggered activity in patients with chronic atrial fibrillation. The [Ca
2+
]i-voltage gain is also 
increased as a consequence of the elevated NCX expression, promoting further the generation of 
DADs (Voigt et al., 2012).  
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The correlation between the occurrence of afterdepolarizations the increased NCX 
expression has been elegantly demonstrated in a recent study by showing that EADs and DADs 
have more frequently developed in regions with higher NCX expression level (Chang et al., 
2013). Notably, this study also demonstrated that inhibition of NCX was able to suppress atrial 
fibrillation. The arrhythmogenic coupling between aberrant SR Ca
2+ 
leak and NCX is also 
present in pulmonary vein myocytes, the ectopic activity of which is an important cause of atrial 
fibrillation. KB-R7943 was shown to reduce this arrhythmogenic activity in pulmonary vein 
myocytes, underlying again the causal role of NCX in generation of ectopic activity 
(Wongcharoen et al., 2006). It can be concluded that although the involvement of NCX in many 
pathological situations leading to atrial fibrillation seems to be convincing, and NCX inhibition 
appears to reduce the elementary arrhythmogenic events at the cellular level, in vivo 
pharmacological studies designed to show the putative beneficial effects on longer time scale are 
still missing. 
 
14. Conclusions 
 
Significance of pharmacological studies designed to assess the therapeutic value of NCX 
and RyR modulation in cardiovascular diseases were discussed in this review. While both RyR 
and NCX inhibition have beneficial effects reflected in improvements of many aspects of cardiac 
disease, and despite the high need for a more successful therapy urged by the high prevalence 
and mortality in cardiovascular diseases, a relatively limited number of compounds are available 
for these targets. Therefore, in order to a successful transition from the preclinical studies to the 
clinical setting, pharmacology of RyR and NXC inhibition should progress in the direction of 
developing drugs with higher specificity and in case of NCX inhibition, with mode-specific 
effect, which could offer more opportunities for the disease-specific adaptation of therapy. 
Pharmacological modulation of NCX is indeed a unique possibility, since by its bimodal 
function it can also increase and decrease SR Ca
2+ 
load. NCX inhibition can therefore be 
beneficial depending on the efficacy of inhibition of the forward and reverse mode activity of 
NCX. As a specific example, although the inhibition of forward mode NCX can be 
antiarrhythmic by reducing Ca
2+
- induced depolarization, it may also result in cellular Ca
2+ 
gain, 
and in turn in an increased diastolic SR Ca
2+ 
leak. In this case the simultaneous inhibition of 
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reverse-mode NCX may help to avoid excess Ca
2+
 load, but at the same time, it may weaken the 
efficacy of ECC, particularly in heart failure, where relative contribution of NCX to ECC is 
increased. Detailed studies are therefore needed to explore the potential benefit of NCX 
inhibition in pathological situations with different Ca
2+ 
handling disturbances. 
Further improvement of therapeutic efficacy using the existing compounds seems to be 
possible as well. RyR and NCX inhibition theoretically could have synergistic effects, which 
could be beneficial under certain conditions such as atrial fibrillation or CPVT. Blockade on 
RyR can weaken the uncontrolled Ca
2+ 
release from the SR. On the other hand, arrhythmogenic 
potential of SR Ca
2+ 
leak can also be attenuated by inhibition of forward mode NCX and thereby 
suppressing the EAD- and/or DAD-induced triggered activity. Combination of these strategies 
could potentially result in improved outcome, however, experimental validation of this approach 
is still required. 
Despite the promising results of preclinical studies, concerns must be taken into account 
regarding the safety of chronic application of drugs interacting with the cellular Ca
2+ 
handling. 
Dantrolene is being used as a muscle relaxant in the clinical practice and safety margins are 
relatively well known for this drug. To our best knowledge, the long-term safety of NCX 
inhibition, however, has not been evaluated yet. The novel, highly specific ORM compounds, 
however, may have great potential in this regard as well. 
In summary, Ca
2+ 
handling has been considered in the context of pathological 
cardiovascular conditions, such as hypertension, heart failure and the most important fatal 
consequence, cardiac arrhythmias, for a long time. Dysregulated RyR and NCX as key players in 
the Ca
2+ 
mishandling have been emerging pharmacological targets with an enormous therapeutic 
potential. Perfecting pharmacological tools in this field could provide us with novel avenues for 
drug treatment which could prevent the development, slow down the progression of the disease, 
and suppress fatal arrhythmias. 
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Figure legends 
 
Figure 1: Bimodal operation of NCX. NCX is the main Ca
2+
 extrusion mechanism when 
operating in its forward mode. However, this operation generates an inward current, which can 
lead to aberrant membrane depolarization and arrhythmia generation. When operating in reverse 
mode, NCX controls the cellular Ca
2+
 load, which can result in cellular Ca
2+
 overlaod and 
pathological Ca
2+
 signaling. 
 
Figure 2: Central role of NCX in vascular smooth muscle cells. Due to co-localization and 
functional coupling with ion-channels and transporters, NCX integrates the vasomotor signals 
and controls the intracellular Ca
2+
 level. Increased reverse NCX activity due to intracellular Na
+
 
load leads to increased vascular responsiveness and hypertension. 
 
Figure 3: Targeting Ca
2+
 handling in heart failure. NCX inhibition can normalize the increased 
Ca
2+
 extrusion from the cell, resulting in elevated Ca
2+
 load of the SR. However, parallel block 
of the reverse NCX may deleteriously affect the Ca
2+
-induced Ca
2+
 release. Inhibition of the 
pathological Ca leak via stabilizing the RyR activity may be useful to increase the SR Ca
2+
 
content, which strengthens the systolic Ca
2+
 release and force of contraction. 
 
Figure 4: Antiarrhythmic action of RyR and NCX inhibition. RyR stabilization inhibits the 
aberrant Ca
2+
 release events, thereby preventing the activation of the forward NCX and the 
development of abnormal membrane depolarizations such as early and delayed 
afterdepolarizations. Parallel inhibition of NCX may have synergistic effects, reducing at the 
same time the cellular Ca
2+
 load via inhibition of the revers NCX activity. 
 
 
